Sterling Capital Management’s Dyne Therapeutics DYN Stock Holding History

Sterling Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.5K	Sell	1,960 -1,321	-40%	-$24.6K	﹤0.01%	1621
2026 Q1	$59.5K	Sell	3,281 -1,885	-36%	-$32.5K	﹤0.01%	1573
2025 Q4	$101K	Sell	5,166 -45	-0.9%	-$852	﹤0.01%	1526
2025 Q3	$65.9K	Buy	5,211 +3,414	+190%	+$38.9K	﹤0.01%	1673
2025 Q2	$17.1K	Buy	1,797 +1,714	+2,065%	+$18.9K	﹤0.01%	1850
2025 Q1	$868	Hold	83	–	–	﹤0.01%	2858
2024 Q4	$1.96K	Hold	83	–	–	﹤0.01%	2793
2024 Q3	$2.98K	Buy	+83	New	+$3.3K	﹤0.01%	1997

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Sterling Capital Management's DYN Position: Q2 2026 in Review

Sterling Capital Management reduced its Dyne Therapeutics (DYN) stake by 40% in Q2 2026, selling an estimated $24.6K and leaving 1,960 shares worth $43.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1621.

Sterling Capital Management first reported a position in DYN in Q3 2024 and has held it in 8 quarters since. The position peaked at $101K in Q4 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Sterling Capital Management held 1,960 shares of Dyne Therapeutics worth $43.5K as of Q2 2026.
Sterling Capital Management sold 1,321 Dyne Therapeutics shares in Q2 2026, an estimated $24.6K.
Dyne Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1621 holding.
Sterling Capital Management first reported a position in Dyne Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Dyne Therapeutics position peaked at $101K in Q4 2025.
246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.